# To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT00917150** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 771 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** tetomilast (OPC-6535)
- **DRUG:** tetomilast (OPC-6535)
- **DRUG:** tetomilast (OPC-6535)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00917150
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 771 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917150, "To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00917150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*